Huons Global Postpones EGM on Subsidiary Merger Awaiting Overlapping Listing Guidelines

Huons Global decided on June 22, 2026, to postpone the extraordinary general meeting originally scheduled for July 3, 2026, as announced by the board.
The postponement is due to unresolved government guidelines on overlapping listings, which are needed to ensure fair voting on the subsidiary merger between Huons and HuonsLab.
The merger aims to strengthen the new drug pipeline and build a full biopharmaceutical value chain, with limited short-term dilution for Huons Global shareholders.
The company maintains a shareholder return policy, having approved a mid-to-long term dividend plan in May 2026.
[AI Summary]Huons Global focuses on creating R&D synergies through the subsidiary merger, but regulatory uncertainty has delayed the schedule. No direct capital change occurs at the parent level, yet the merger is expected to enhance long-term shareholder value. Investment risk is neutral at current price; monitor further disclosures after guideline finalization.